Literature DB >> 27568993

What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database.

Valeria Guglielmi1, Alfonso Bellia1, Serena Pecchioli2, Gerardo Medea3, Damiano Parretti3, Davide Lauro1, Paolo Sbraccia1, Massimo Federici1, Iacopo Cricelli2, Claudio Cricelli3, Francesco Lapi4.   

Abstract

BACKGROUND: There are some inconsistencies on prevalence estimates of familial hypercholesterolemia (FH) in general population across Europe due to variable application of its diagnostic criteria. We aimed to investigate the FH epidemiology in Italy applying the Dutch Lipid Clinical Network (DLCN) score, and two alternative diagnostic algorithms to a primary care database.
METHODS: We performed a retrospective population-based study using the Health Search IMS Health Longitudinal Patient Database (HSD) and including active (alive and currently registered with their general practitioners (GPs)) patients on December 31, 2014. Cases of FH were identified by applying DLCN score. Two further algorithms, based on either ICD9CM coding for FH or some clinical items adopted by the DLCN, were tested towards DLCN itself as gold standard.
RESULTS: We estimated a prevalence of 0.01% for "definite" and 0.18% for "definite" plus "probable" cases as per the DLCN. Algorithms 1 and 2 reported a FH prevalence of 0.9 and 0.13%, respectively. Both algorithms resulted in consistent specificity (1: 99.10%; 2: 99.9%) towards DLCN, but Algorithm 2 considerably better identified true positive (sensitivity=85.90%) than Algorithm 1 (sensitivity=10.10%).
CONCLUSION: The application of DLCN or valid diagnostic alternatives in the Italian primary care setting provides estimates of FH prevalence consistent with those reported in other screening studies in Caucasian population. These diagnostic criteria should be therefore fostered among GPs. In the perspective of FH new therapeutic options, the epidemiological picture of FH is even more relevant to foresee the costs and to plan affordable reimbursement programs in Italy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dutch Lipid Clinical Network; Familial hypercholesterolemia; Primary care

Mesh:

Substances:

Year:  2016        PMID: 27568993     DOI: 10.1016/j.ijcard.2016.08.269

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care.

Authors:  Valeria Guglielmi; Alfonso Bellia; Elisa Bianchini; Gerardo Medea; Iacopo Cricelli; Paolo Sbraccia; Davide Lauro; Claudio Cricelli; Francesco Lapi
Journal:  Endocrine       Date:  2017-09-14       Impact factor: 3.633

2.  Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014).

Authors:  Emily M Bucholz; Angie Mae Rodday; Katherine Kolor; Muin J Khoury; Sarah D de Ferranti
Journal:  Circulation       Date:  2018-03-26       Impact factor: 29.690

3.  To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care.

Authors:  Francesco Lapi; Ettore Marconi; Ignazio Grattagliano; Alessandro Rossi; Diego Fornasari; Alberto Magni; Pierangelo Lora Aprile; Claudio Cricelli
Journal:  Intern Emerg Med       Date:  2022-07-30       Impact factor: 5.472

Review 4.  Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.

Authors:  Leo E Akioyamen; Jacques Genest; Shubham D Shan; Rachel L Reel; Jordan M Albaum; Anna Chu; Jack V Tu
Journal:  BMJ Open       Date:  2017-09-01       Impact factor: 2.692

5.  Screening and treatment of familial hypercholesterolemia in a French sample of ambulatory care patients: A retrospective longitudinal cohort study.

Authors:  Jean Ferrières; Victoria Banks; Demetris Pillas; Francesco Giorgianni; Laurene Gantzer; Beranger Lekens; Lea Ricci; Margaux Dova-Boivin; Jean-Vannak Chauny; Guillermo Villa; Gaelle Désaméricq
Journal:  PLoS One       Date:  2021-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.